Targeting MicroRNAs with Small Molecules

Abstract

MicroRNAs (miRs) have been implicated in numerous diseases, presenting an attractive target for the development of novel therapeutics. The various regulatory roles of miRs in cellular processes underscore the need for precise strategies. Recent advances in RNA research offer hope by enabling the identification of small molecules capable of selectively targeting specific disease-associated miRs. This understanding paves the way for developing small molecules that can modulate the activity of disease-associated miRs. Herein, we discuss the progress made in the field of drug discovery processes, transforming the landscape of miR-targeted therapeutics by small molecules. By leveraging various approaches, researchers can systematically identify compounds to modulate miR function, providing a more potent intervention either by inhibiting or degrading miRs. The implementation of these multidisciplinary approaches bears the potential to revolutionize treatments for diverse diseases, signifying a significant stride towards the targeting of miRs by precision medicine.

Identification and Application of Emerging Biomarkers in Treatment of Non-Small-Cell Lung Cancer: Systematic Review

“…Additional studies are needed to refine the cut-off points for the bTMB and evaluate its predictive efficacy in different treatment combinations, with an emphasis on genetic heterogeneity and the impact on treatment responses [132,133]. Future research on miRNAs should focus on identifying specific profiles associated with the treatment response and disease progression, as well as developing targeted therapies that modulate miRNA levels to enhance the treatment efficacy [134,135]. Regarding PD-L1, further research is needed to understand the heterogeneity in PD-L1 expression and its impact on the treatment response, exploring therapeutic combinations that can overcome resistance in specific subgroups [99,110].…”